The Exophthalmos Treatment Market Size is expected to be worth US$ 271.8 million in fiscal year 2023, up from US$ 251.2 million in fiscal year 2022. The global market is expected to grow steadily between 2023 and 2033, reaching US$ 598 million by the end of that year.
Exophthalmos is most commonly caused by Graves’ disease. About 25 to 50 percent of persons with this illness will have ocular involvement. It’s worth noting that ocular impairment can arise up to 20 years after a thyroid disease is diagnosed, or up to 10 years before. These illnesses were a major influence in exophthalmos therapy from 2023 to 2033.
According to a study published in September 2020 by Biomed Central Ltd, the prevalence of exophthalmos sickness patients worldwide was roughly 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism. As a result, the rising incidence of exophthalmos ailment among people is fueling market growth globally and is expected to do so in the future, propelling the study market’s rise during the forecast period.
Unlock growth potential with industry expertise. Download your market sample report now: https://www.futuremarketinsights.com/reports/sample/rep-gb-16487
In terms of region, North America is predicted to be the most lucrative market for exophthalmos illnesses. According to estimates published by the American Academy of Ophthalmology in July 2022, around 18 out of every 100,000 Americans suffer from exophthalmos sickness. Simultaneously, new pharmacological and therapeutic innovations have propelled the regional market to new heights. During the projected period, such advancements are expected to create new opportunities for area producers.
Key Takeaways from the Market Study:
- During the period from 2018 to 2022, the market for Exophthalmos Treatment grew at a CAGR of 6.4%.
- From 2023 to 2033, the market for Exophthalmos Treatment is predicted to increase at an 8.2% CAGR.
- The non-surgical category by treatment type is expected to dominate in 2023, accounting for 53% of total revenue.
- The specialised clinic sector by end-user will be the second-largest segment during the forecast period, with a 25% market share in 2023.
- From 2023 to 2033, the North American region is predicted to grow at an 8.7% CAGR.
- The Asia Pacific exophthalmos therapy market is expected to grow at a 7.1% CAGR between 2023 and 2033.
“The increasing incidences of hyperthyroidism along with Graves’ disease have been accelerating the growth of the global exophthalmos market during the forecast period.” comments a Future Market Insights analyst.
Exophthalmos Treatment Market Report Available At a Discounted Price: https://www.futuremarketinsights.com/request-discount/rep-gb-16487
Competitive Landscape:
Some of the top players in the global exophthalmos disease market are:
- Eyevance Pharmaceuticals
- Sling Therapeutics
- Competition Deep Dive
- AbbVie
- Alcon
- Avik Pharma
- Anuh Pharma Ltd.
- Pfizer CentreOne
- Pipelinepharma
- Mylan N.V.
- Manus Aktteva Biopharma LLP
- Roche
Some of the recent developments in this domain are:
- EyeBiotech Ltd., a privately owned ophthalmology biotechnology business seeking to develop a new generation of eye disease therapeutics, announced the successful conclusion of a $65 million Series A fundraising round in 2022. Samsara BioCapital, Jeito Capital, and SV Health Investors spearheaded the round, with additional funding provided by MRL Ventures. A multinational team of executives as well as investors with a long history of creating ground-breaking ophthalmology medicines are brought together for the Series A.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Exophthalmos Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
Request Tailored Insights to Outperform in the Exophthalmos Treatment Market: https://www.futuremarketinsights.com/customization-available/rep-gb-16487
Key Segments Covered In The Exophthalmos Treatment Market Report
Exophthalmos Treatment Market By Treatment:
- Non-surgical Treatment
- Sympathomimetic Amines
- Corticosteroids
- Secondary Metabolites
- Monoclonal Antibodies
- Radiotherapy
- Surgical Treatment
- Orbital Decompression
- Eye Muscle Surgery
- Eyelid Surgery
Exophthalmos Treatment Market By End User:
- Hospital Pharmacies
- Specialty Clinics
- Others
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
